IP Library › Granted Patent US 12,440,540
Granted Patent B2
US 12,440,540 · App. 18/189,116 · Granted Oct 14, 2025

IL-2 orthologs and methods of use

Inventors: Paul-Joseph Penaflor-Aspuria (Redwood City, CA); Scott Alan McCauley (Menlo Park, CA); Martin Oft (Palo Alto, CA); Steve Kauder (Menlo Park, CA)
Assignee: Synthekine, Inc.
A61K38/2013A61K39/3955A61K39/4611A61K39/464C07K14/55C12N5/0636C12N15/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,540
App. No.
18/189,116
Granted
Oct 14, 2025
Kind
B2
Abstract

The present disclosure relates to hIL2 orthogonal ligands (“IL2 orthologs”) that specifically and selectively bind to the extracellular domain (ECD) a transmembrane polypeptide comprising of a modified hCD122 polypeptide. The binding of the hIL2 ortholog to the modified hCD122 polypeptide participates in the transduction pathway of intracellular signaling resulting in a biological activity of the native intracellular signaling patterns associated with hIL2 binding to either the intermediate or high affinity hIL2 receptor but which exhibits selectivity to an engineered cell expressing an hCD122 orthogonal receptor. The hIL2 orthologs of the present invention exhibit significantly reduced binding relative to their binding to the extracellular domain of wild type hCD122, either alone or when hCD122 is present in the form of an endogenous high or intermediate affinity hIL2 receptors.

Claims (8)

1. A nucleic acid sequence encoding a human IL2 (hIL2) ortholog polypeptide consisting of the amino acid sequence set forth in SEO ID NO:20.

2. A recombinant vector comprising the nucleic acid sequence of claim 1 .

3. A cell comprising the nucleic acid of claim 1 .

4. The cell of claim 3 , wherein the cell is a prokaryotic cell.

5. The cell of claim 3 , wherein the cell is a eukaryotic cell.

6. A cell comprising the recombinant vector of claim 2 .

7. The cell of claim 6 , wherein the cell is a prokaryotic cell.

8. The cell of claim 6 , wherein the cell is a eukaryotic cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2023
From: PENAFLOR-ASPURIA, PAUL-JOSEPH; MCCAULEY, SCOTT A; OFT, MARTIN; KAUDER, STEVE
To: SYNTHEKINE, INC.
Reel/Frame 063098/0959 →
Continuity (3)
Continuation 17119923 · Dec 11, 2020
Provisional Application 62948066 · Dec 13, 2019
Related Publication 20230381278A1 · Nov 30, 2023
References Cited (37)
US 4902502A · Nitecki · 1990 [cited by applicant]
US 5037644A · Shaked et al. · 1991 [cited by applicant]
US 6955807B1 · Shanafelt · 2005 [cited by applicant]
US 10869887B2 · Garcia et al. · 2020 [cited by applicant]
US 11439664B2 · Garcia et al. · 2022 [cited by applicant]
US 20030166163A1 · Gillies et al. · 2003 [cited by applicant]
US 20030171267A1 · Rosen · 2003 [cited by applicant]
US 20060199250A1 · Zhao et al. · 2006 [cited by applicant]
US 20110250213A1 · Tsao et al. · 2011 [cited by applicant]
US 20130017168A1 · Gillies et al. · 2013 [cited by applicant]
US 20140255360A1 · Spencer et al. · 2014 [cited by applicant]
US 20140349402A1 · Cooper et al. · 2014 [cited by applicant]
US 20180228842A1 · Garcia et al. · 2018 [cited by applicant]
US 20190083635A1 · Xie et al. · 2019 [cited by applicant]
US 20200024319A1 · Butz et al. · 2020 [cited by applicant]
US 20210069243A1 · Garcia et al. · 2021 [cited by applicant]
JP 2005511707A · 2005 [cited by applicant]
WO 1999047178A1 · 1999 [cited by applicant]
WO 2003048334A2 · 2003 [cited by applicant]
WO 2005086751A2 · 2005 [cited by applicant]
WO 2016025385A1 · 2016 [cited by applicant]
WO 2017044464A1 · 2017 [cited by applicant]
WO 2019173773A1 · 2019 [cited by applicant]
WO 2020131547A1 · 2020 [cited by applicant]
Bork P. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome research. Apr. 1, 2000;10(4):398-400. [cited by applicant]
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science. Mar. 16, 1990;247(4948):1306-10. [cited by applicant]
Burgess et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single l… [cited by applicant]
Calvello et al. Conservation/Mutation in the splice sites of cytokine receptor genes of mouse and human. International journal of evolutionary biology. 2013;2013. [cited by applicant]
Cochran et al. Improved mutants from directed evolution are biased to orthologous substitutions. Protein Engineering, Design and Selection. Jun. 1, 2006;19(6):245-53. [cited by applicant]
Ho et al. Decoupling the functional pleiotropy of stem cell factor by tuning c-Kit signaling. Cell. Mar. 9, 2017;168(6):1041-52. [cited by applicant]
Imler et al. Identification of three adjacent amino acids of interleukin-2 receptor beta chain which control the affinity and the specificity of the interaction with interleukin-2. The EMBO Journal. Jun. 1992;11(6):2047… [cited by applicant]
Lazar et al. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology. Mar. 1988;8(3):1247-52. [cited by applicant]
Mitra et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. May 19, 2015;42(5):826-38. [cited by applicant]
Ring et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nature immunology. Dec. 2012;13(12):1187-95. [cited by applicant]
Shi et al. A novel cytokine receptor-ligand pair: identification, molecular characterization, and in vivo immunomodulatory activity. Journal of Biological Chemistry. Jun. 23, 2000;275(25):19167-76. [cited by applicant]
Sockolosky et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. Mar. 2, 2018;359(6379):1037-42. [cited by applicant]
Wang et al. Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and yc Receptors. Science. Nov. 18, 2005;310(5751):1159-63. [cited by applicant]